article thumbnail

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. Media: media@mymd.com. in the blood. 646) 421-9523.

article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Press Release: MAPS Places Fully Validated, Multi-Kilogram Synthesis of MDMA in the Public Domain?

Cannabis Law Report

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. MEDIA CONTACT . 831-429-6362 ext 303.

article thumbnail

Compass Pathways granted fifth US patent for crystalline psilocybin

Cannabis Law Report

COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America.

article thumbnail

Press Release: COMPASS Pathways plc financial results second quarter 2021 – Reminds us of that rich people’s festival in the desert

Cannabis Law Report

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. Business highlights.

article thumbnail

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cannabis Law Report

Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials.

article thumbnail

Today’s Answer of the Day

TheAnswerPage

According to reports in the media and statements on various CBD websites, CBD has anti-depressant effects. Do the results of randomized clinical trials support those claims? April 2019 systematic review on the role of cannabidiol in psychiatry found that CBD has no efficacy in depression and bipolar disorders.